<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204032</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-104</org_study_id>
    <nct_id>NCT03204032</nct_id>
  </id_info>
  <brief_title>A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor</brief_title>
  <official_title>A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and&#xD;
      safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and&#xD;
      Thalidomide in subjects with Advanced Extrapancreatic Neuroendocrine Tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance to the toxicity or PD (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerable toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)(a year later) up to PD or death (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Extrapancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur</intervention_name>
    <description>Tegafur 40-60mg po bid(d1-d14);</description>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>200mg po qd(d10-d14)</description>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)</description>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients should participate in the study voluntarily and sign informed consent;&#xD;
&#xD;
          2. Histopathological proven diagnosis of low and intermediate grade (G1, G2 or G3)&#xD;
             advanced Extrapancreatic neuroendocrine tumor( locally advanced, unresectable or&#xD;
             distant Metastatic). For gastroenteropancreatic neuroendocrine tumor（GEP-NET）,the&#xD;
&#xD;
             - Page 4 of 5 [DRAFT] - classification is based on nuclear mitotic number and the&#xD;
             Ki-67 index,which are as follows:G1:Nuclear mitotic number &lt;2/10HPF,Ki-67&#xD;
             proliferative index ≤2%.G2: Nuclear mitotic number 2～20/10HPF,Ki-67 proliferative&#xD;
             index 3%～20%.G3 Nuclear mitotic number &gt; 20/10HPF,Ki-67 proliferative index &gt;20%;&#xD;
&#xD;
          3. Patients with advanced Extrapancreatic neuroendocrine tumor who had not been treated&#xD;
             or had no more than two kinds of Systemic Anti-tumor Therapy,which could be&#xD;
             somatostatin analogs, interferon, PRRT (peptide receptor radionuclide therapy), mTOR&#xD;
             inhibitors, or chemotherapy (without any use of azole amines, fluorouracil,or&#xD;
             thalidomide chemotherapy drugs);&#xD;
&#xD;
          4. Radiological documentation of tumor progression is required within 12months prior to&#xD;
             randomization;&#xD;
&#xD;
          5. At least one measurable lesion (byRECIST1.1);&#xD;
&#xD;
          6. ANC≥1.5×109/L,PLT≥100×109/L,HB≥90g/L,TBIL≤1.5ULN ;Without supportive care, ALT≤2.5ULN&#xD;
             and ALP≤2.5ULN (without hepatic metastasis) ALT≤5ULN and ALP≤5ULN(with hepatic&#xD;
             metastasis);serum creatin ≤1.5ULN and creatinine clearance rate&#xD;
&#xD;
             ≥60ml/min；INR≤1.5ULN and APTT ≤1.5ULN ;&#xD;
&#xD;
          7. ECOG PS:0-1;&#xD;
&#xD;
          8. Life expectancy of more than 12 weeks;&#xD;
&#xD;
          9. Men/Women of childbearing potential must agree to use a highly effective contraceptive&#xD;
             method (such as double barrier contraceptive method，condom, oral or injectable&#xD;
             contraceptives and intrauterine device) throughout treatment and for at least 90 days&#xD;
             after study completion；All female patients will be considered fertile unless she has&#xD;
             undergone natural menopause, artificial menopause or sterilization (such as&#xD;
             hysterectomy, bilateral adnexal resection, or radioactive ovarian irradiation etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1、Diagnosed with high grade (G3) neuroendocrine carcinomas, adenocarcinoma, pancreatic&#xD;
             islet cell carcinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma, and&#xD;
             small cell carcinoma; 2、Functional NET which needs concomiant use of long-acting&#xD;
             somatostatin analogues to control symptoms such as insulinoma, gastrinoma, glucagon&#xD;
             tumor, somatostatin, ACTH tumor, VIP tumor, and carcinoid syndrome, Zollinger-Ellison&#xD;
             syndrome or other disease-specific active symptoms.&#xD;
&#xD;
             3、Have received anti-vascular endothelial growth factor（VEGF）/VEGFR targeted drugs and&#xD;
             progressed upon these drugs 4、Urinalysis shows urine protein ≥ 2+ or 24-hour protein&#xD;
             quantity test shows urinary protein ≥1 g; 5、Serum potassium, calcium (albumin-bound&#xD;
             ionic or corrected) or magnesium exceed the normal range with clinical significance；&#xD;
             6、Under anti-hypertension treatment, still uncontrolled hypertension, defined as:&#xD;
             systolic blood pressure &gt;140 mmHg or diastolic blood pressure &gt;90 mmHg;&#xD;
             7、Gastrointestinal disease or condition that investigators suspect may affect drug&#xD;
             absorption, including, but not limited to, active gastric and duodenal ulcers,&#xD;
             ulcerative colitis and other digestive disease, gastrointestinal tumor with active&#xD;
             bleeding, or other gastrointestinal conditions that may cause bleeding or perforation&#xD;
             by investigator's discretion; 8、History or presence of a serious hemorrhage (&gt;30 ml&#xD;
             within 3 months), hemoptysis (&gt;5 ml blood within 4 weeks) or a thromboembolic event&#xD;
             (including transient ischemic attack) within 12 months; 9、Clinically significant&#xD;
             cardiovascular disease, including but not limited to, acute myocardial infarction&#xD;
             within 6 months prior to enrollment, severe/unstable angina pectoris or coronary&#xD;
             artery bypass grafting, congestive heart failure according to the New York Heart&#xD;
             Association (NYHA) classification ≥ 2; ventricular arrhythmias which needs drug&#xD;
             treatment; LVEF (LVEF) &lt;50%; 10、Mean corrected QT interval (QTc) ≥ 480 msec; 11、Other&#xD;
             malignancies diagnosed within the previous 5 years, except basal cell carcinoma or&#xD;
             cervical carcinoma in situ after radical resection; 12、Anti-tumor therapy received&#xD;
             within 4 weeks prior to the initiation of the investigational treatment, including,&#xD;
             but not limited to, chemotherapy, radical radiotherapy, targeted therapy,&#xD;
             immunotherapy and anti-tumor Chinese medicine treatment, hepatic chemoembolization,&#xD;
             cryoablation and radiofrequency ablation ; 13、Palliative radiotherapy for a bone&#xD;
             metastasis lesion within 2 weeks prior to the initiation of the investigational&#xD;
             treatment; 14、Any clinically significant active infection, including, but not limited&#xD;
             to, human immunodeficiency virus (HIV) infection; 15、History of clinically significant&#xD;
             hepatic disease, including, but not limited to, known hepatitis B virus (HBV)&#xD;
             infection with HBV DNA positive (copies ≥1×104/ml); known Hepatitis C virus （HCV)&#xD;
             infection with HCV RNA positive (copies ≥1×103/m); or liver cirrhosis, etc.&#xD;
&#xD;
             16、Surgery (except biopsy) within 28 days prior to the initiation of investigational&#xD;
             treatment or unhealed surgical incision; 17、Brain metastases and/or spinal cord&#xD;
             compression not treated by surgery and/or radiotherapy, and with no clinical imaging&#xD;
             evidence of disease stability; 18、Toxicity from a previous anti-tumor treatment that&#xD;
             does not return to Grade 0 or 1 (except for hair loss);&#xD;
&#xD;
             19、Received investigational treatments in other clinical studies within 4 weeks prior&#xD;
             to enrollment; 20、Women who are pregnant or lactating; 21、Other disease, metabolic&#xD;
             disorder, physical examination anomaly, abnormal laboratory result, or any other&#xD;
             conditions are inappropriate for the use of the investigational product or affect&#xD;
             interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yihebali Chi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <email>dryihebalichi@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao, doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihebali Chi, doctor</last_name>
      <email>yihebalichi@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>yihebali chi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tegafur</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Extrapancreatic Neuroendocrine Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

